Eligible patients were enrolled from hospitals worldwide and were centrally randomised ( 1:1 ) to chemotherapy ( type selected by the investigator ; multidrug for at least four courses recommended ) or no chemotherapy , using permuted blocks , and stratified by previous chemotherapy , oestrogen-receptor and progesterone-receptor status , and location of ILRR .